Contingency Management for Stimulant Use Disorder

(MIMIC2 Trial)

Recruiting at 13 trial locations

Overseen By Medical Director of Behavioral Health Chicago Department of Pu

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Northwestern University

Must be taking: Opioid use disorder medications

Disqualifiers: Under 18, No electronic records

Stay on Your Current Meds You can continue your current medications while participating

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

76 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a method called the Science of Service Laboratory to assist individuals with stimulant use disorder, particularly those also facing opioid use disorder. The goal is to determine if this approach can be effectively integrated into existing opioid treatment programs. The Science of Service Laboratory provides training, feedback, and support for treatment program staff. The trial seeks counselors who work with opioid use disorder patients, offering support such as counseling sessions.

As an unphased trial, this study presents a unique opportunity to contribute to innovative treatment strategies and enhance support for those in need.

Will I have to stop taking my current medications?

The trial protocol does not specify whether participants must stop taking their current medications. It seems to focus on adding contingency management to existing treatments for opioid use disorder.

What prior data suggests that the Science of Service Laboratory implementation strategy is safe?

Research has shown that contingency management, part of the Science of Service Laboratory strategy, offers a promising way to treat stimulant use disorder. This method uses rewards to encourage positive actions, like staying drug-free, and complements other treatments for opioid use disorder.

Studies have found that this approach works well in opioid treatment programs. Although specific safety data on the Science of Service Laboratory strategy is lacking, it primarily focuses on training and supporting healthcare providers rather than directly treating patients, making it unlikely to harm patients.

Overall, contingency management is well-received and has been used successfully in treatment settings without major safety issues. Since this approach has been tested in real-world situations, it is considered safe to use. ^{1 2 3 4 5}

Why are researchers excited about this trial?

Researchers are excited about the Contingency Management for Stimulant Use Disorder trial because it focuses on a unique implementation strategy for delivering behavioral treatment. Unlike traditional methods that might focus solely on therapy or medication, this approach combines didactic training, performance feedback, and facilitation to reinforce positive behavior changes. The Science of Service Laboratory's strategy includes workshops, coaching calls, and feedback sessions, which aim to enhance the effectiveness and adoption of contingency management in real-world settings. This comprehensive approach has the potential to improve treatment outcomes by offering a structured and supportive framework for both patients and healthcare providers.

What evidence suggests that the Science of Service Laboratory is effective for stimulant use disorder?

Research shows that contingency management (CM) effectively treats stimulant use disorder. CM involves giving small rewards to encourage drug-free behavior. Studies have found that CM is the most effective behavioral therapy for helping people adhere to their treatment for stimulant use. It works especially well when combined with medication for opioid use disorder. This trial tests the Science of Service Laboratory implementation strategy to enhance CM delivery in treatment programs and improve patient outcomes. ^{1 2 4 6 7}

Who Is on the Research Team?

Sara Becker

Principal Investigator

Northwestern University

Are You a Good Fit for This Trial?

This trial is for adults who are currently receiving medication for opioid use disorders within the last 30 days and also use stimulants, as shown by self-report or positive tests. They must be actively managing patient cases and providing psychosocial support. It's not open to those under 18, unable to consent, or without electronic medical records.

Inclusion Criteria

I am currently managing a group of patients.

I provide counseling support to patients using medication for opioid addiction.

I started medication for opioid addiction in the last 30 days and have used stimulants recently.

Exclusion Criteria

I am under 18 and on medication for opioid use disorder.

I am on medication for opioid use disorder and do not have electronic medical records.

I am under 18 years old.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Implementation

Implementation of the Science of Service Laboratory strategy, including didactic training, performance feedback, and facilitation

10 months

Monthly facilitation calls and coaching sessions

Data Collection

Collection of de-identified electronic medical record data and staff feedback at six intervals

10 months

Follow-up

Participants are monitored for safety and effectiveness after implementation

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Science to Service Laboratory

Trial Overview The study is testing a strategy called Science of Service Laboratory designed to help opioid treatment programs implement contingency management for patients with stimulant use disorder. The effectiveness of this multi-level approach will be measured in terms of its adoption by staff and impact on patient outcomes.

How Is the Trial Designed?

Group I: Science of Service Laboratory implementation strategy Experimental Treatment 1 Intervention

The Science of Service Laboratory implementation strategy consists of: didactic training (contingency management workshops; monthly contingency management coaching calls), performance feedback (practice sessions and electronic medical record feedback); and facilitation (monthly facilitation calls).

Group II: Stepped wedge comparator Active Control 1 Intervention

Our hybrid trial uses a unidirectional crossover stepped wedge design. All sites cross over in the same direction from usual care to intervention. All sites therefore act as their own comparison prior to the sequential roll-out of the implementation strategy.

Who Is Running the Clinical Trial?

Northwestern University

Lead Sponsor

Trials

1,674

Recruited

989,000+

National Institute on Drug Abuse (NIDA)

Collaborator

Trials

2,658

Recruited

3,409,000+

Stanford University

Collaborator

Trials

2,527

Recruited

17,430,000+

Ohio State University

Collaborator

Trials

891

Recruited

2,659,000+

Published Research Related to This Trial

A new standardized strategy for reporting adverse events (AEs) and serious adverse events (SAEs) in substance use disorder (SUD) clinical trials was developed, which aims to reduce the reporting burden while maintaining safety monitoring.

In a review of 17 SUD trials involving 6737 participants, the new strategy showed a significant reduction in irrelevant safety event reporting, leading to a more consistent safety assessment system tailored to the risks associated with specific trial interventions.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Strategies for safety reporting in substance abuse trials. Lindblad, R., Campanella, M., Styers, D., et al.[2013]

Telehealth-based contingency management (CM) for stimulant use disorder has shown preliminary feasibility and acceptability, allowing participants to successfully engage in treatment and verify abstinence through self-administered oral fluid testing.

Improvements are needed in the remote interpretation of toxicology test results to ensure accurate detection of abstinence, which is critical for delivering therapeutic incentives effectively.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Telehealth-Based Contingency Management Targeting Stimulant Abstinence: A Case Series from the COVID-19 Pandemic. Forster, SE., Torres, TM., Steinhauer, SR., et al.[2023]

Contingency management (CM) is a highly effective intervention for stimulant use and works well with medication for opioid use disorder, yet its implementation in opioid treatment programs is surprisingly low, highlighting a significant gap in addiction health services.

This study will evaluate a multi-level implementation strategy called the Science of Service Laboratory (SSL) across 10 opioid treatment programs to promote CM, using a robust trial design to assess both implementation and patient outcomes over time.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Implementing contingency management for stimulant use in opioid treatment programs: protocol of a type III hybrid effectiveness-stepped-wedge trial. Becker, SJ., DiClemente-Bosco, K., Scott, K., et al.[2023]

Contingency management programs, which reward behavior change to reduce stimulant use, are currently the most effective treatment for stimulant use disorder, but they are often hard to access.

A case study of a patient with osteomyelitis showed that adapting these programs to an inpatient hospital setting can significantly improve treatment outcomes for individuals with stimulant use disorders.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

An Acute Care Contingency Management Program for the Treatment of Stimulant Use Disorder: A Case Report. Bach, P., Garrod, E., Robinson, K., et al.[2022]

Contingency management (CM) is an effective treatment for stimulant use disorders, and this guide provides a structured protocol to enhance its implementation in clinical settings.

The article emphasizes the importance of adhering to evidence-based practices in CM, as poorly designed programs are unlikely to improve patient outcomes, highlighting the need for careful planning and preparation.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Implementing an evidence-based prize contingency management protocol for stimulant use. Rash, CJ.[2023]

Citations

1. clinicaltrials.gov clinicaltrials.gov/study/NCT05702021

Implementing Contingency Management for Stimulant Use ... This project evaluates a multi-level implementation strategy, the Science to Service Laboratory, to install contingency management for stimulant use in opioid ...

2. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC10498624/

Implementing contingency management for stimulant use ... Contingency management (CM) is an evidence-based intervention for stimulant use and is highly effective in combination with medication for opioid use disorder.

3. clinicaltrial.be clinicaltrial.be/en/details/189873?per_page=20&recruiting=1&enrolling_by_invitation=1&active_not_recruiting=1&not_yet_recruiting=0&completed=0&only_recruiting=0&only_eligible=0

Implementing Contingency Management for Stimulant Use ... This project evaluates a multi-level implementation strategy, the Science to Service Laboratory, to install contingency management for stimulant ...

4. sciencedirect.com sciencedirect.com/science/article/pii/S2949875922000121

Community implementation of contingency management to ... Notably, research has recognized CM as the most effective among behavior therapies for addressing treatment adherence by persons with stimulant use disorder (De ...

5. pubmed.ncbi.nlm.nih.gov pubmed.ncbi.nlm.nih.gov/37705093/

protocol of a type III hybrid effectiveness-stepped-wedge trial Contingency management (CM) is an evidence-based intervention for stimulant use and is highly effective in combination with medication for opioid use disorder.

6. d-nb.info d-nb.info/1318547415/34

protocol of a type III hybrid effectiveness-stepped-wedge This protocol aims to implement contingency man- agement—one of the most effective, yet least available behavioral treatments for stimulants— ...

7. health.ny.gov health.ny.gov/health_care/medicaid/ebbrac/2025/docs/2025-04-02_contingency_mgmt_sud_rpt.pdf

Contingency Management for Stimulant Use Disorder Health ... England Science to Service Laboratory. J Subst Abuse Treat. 2008;34(3):293 ... available data does not represent post-implementation outcomes. Michigan ...